More news about Elanix Technologies

First Clinical Study with Elanix’ Progenitor Cells

08.08.2017 17:23

Related tags

Study

Elanix announced today the treatment of the first patient in a Phase I/II clinical trial with TWB-103 in adults with skin graft donor site wounds. The study is being conducted in Taiwan and Japan with partner Transwell Biotech. TWB-103 is a novel gel formulation developed by Transwell Biotech, using skin fibroblast progenitor cells provided by Elanix.

Elanix  develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing.

 “The start of the first human studies of TWB-103 is a significant milestone in our plan to build a regenerative medicine franchise in acute wound healing based on our proprietary progenitor cell technology. This gets us one step closer to introducing an acute wound care treatment to the market which could benefit over two million patients worldwide that are hospitalised for burns annually,” stated Tomas Svoboda, CEO of Elanix Biotechnologies. “The team at Transwell has been very efficient in advancing a solid clinical strategy in Asia."

“TWB-103 is a key part of our future wound-care pipeline. The first patient has now been treated and this clinical milestone is a major step for Transwell Biotech and one that we intend to expand to other Asian markets this year,” said Dr. Sean Chen, General Manager of Transwell Biotech.

The study will be conducted at the Tri-Service General Hospital in Taipei as well as the Tokyo Medical University Hospital and the Nippon Medical School Hospital in Tokyo. The aim is to compare safety and efficacy of TWB-103 with standard of care Tegaderm skin dressing to Tegaderm alone in 30 individuals. Primary objectives are safety and healing time from DSW creation to 100% re-epithelialization.

(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS